Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial

BACKGROUND: In patients with type 2 diabetes mellitus, sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of ertugliflozin on HHF and related outcomes. METHODS: VERTIS CV (Evaluation of Ertugliflozin Efficacy and Safety Cardio...

Descripción completa

Detalles Bibliográficos
Autores principales: Cosentino, Francesco, Cannon, Christopher P., Cherney, David Z.I., Masiukiewicz, Urszula, Pratley, Richard, Dagogo-Jack, Sam, Frederich, Robert, Charbonnel, Bernard, Mancuso, James, Shih, Weichung J., Terra, Steven G., Cater, Nilo B., Gantz, Ira, McGuire, Darren K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717477/
https://www.ncbi.nlm.nih.gov/pubmed/33026243
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7717477/
https://www.ncbi.nlm.nih.gov/pubmed/33026243
http://dx.doi.org/10.1161/CIRCULATIONAHA.120.050255

Ejemplares similares